Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 12, 2021
Share
Sinphar Pharmaceutical Co.,Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 608.390 million compared to TWD 583.059 million a year ago. Operating income was TWD 3.235 million compared to operating loss of TWD 25.171 million a year ago. Net income was TWD 5.306 million compared to TWD 8.541 million a year ago. Basic earnings per share from continuing operations was TWD 0.03 compared to TWD 0.05 a year ago. For the half year, sales was TWD 1,225.234 million compared to TWD 1,208.451 million a year ago. Operating loss was TWD 10.023 million compared to TWD 12.355 million a year ago. Net income was TWD 10.340 million compared to TWD 35.312 million a year ago. Basic earnings per share from continuing operations was TWD 0.06 compared to TWD 0.21 a year ago.
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Companyâs principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
SINPHAR PHARMACEUTICAL CO.,LTD. 
